147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 147,000 shares of the company's stock, valued at approximately $1,287,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of IBRX. Doliver Advisors LP increased its holdings in ImmunityBio by 100.0% in the 2nd quarter. Doliver Advisors LP now owns 100,000 shares of the company's stock worth $876,000 after buying an additional 50,000 shares during the period. Strategic Investment Solutions Inc. IL lifted its stake in ImmunityBio by 2,374.7% during the 2nd quarter. Strategic Investment Solutions Inc. IL now owns 11,037 shares of the company's stock valued at $97,000 after acquiring an additional 10,591 shares during the period. Collective Family Office LLC lifted its stake in ImmunityBio by 3.1% during the 2nd quarter. Collective Family Office LLC now owns 157,200 shares of the company's stock valued at $1,376,000 after acquiring an additional 4,693 shares during the period. Vestor Capital LLC purchased a new stake in shares of ImmunityBio in the 1st quarter valued at $88,000. Finally, Arete Wealth Advisors LLC purchased a new stake in shares of ImmunityBio in the 1st quarter valued at $4,500,000. Institutional investors and hedge funds own 8.58% of the company's stock.

Insider Buying and Selling

In other ImmunityBio news, Director Cheryl Cohen sold 131,210 shares of ImmunityBio stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total value of $1,246,495.00. Following the completion of the transaction, the director owned 125,386 shares of the company's stock, valued at approximately $1,191,167. The trade was a 51.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of ImmunityBio stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total transaction of $197,000.00. Following the completion of the transaction, the director directly owned 2,802,788 shares of the company's stock, valued at $22,085,969.44. The trade was a 0.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 435,443 shares of company stock valued at $3,918,819. Corporate insiders own 66.10% of the company's stock.

ImmunityBio Trading Down 1.0%

Shares of NASDAQ:IBRX opened at $7.57 on Friday. ImmunityBio, Inc. has a 12-month low of $1.95 and a 12-month high of $12.43. The business has a 50 day moving average of $7.70 and a two-hundred day moving average of $7.69. The company has a market capitalization of $8.02 billion, a PE ratio of -7.80 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to analyst estimates of $49.70 million. Equities research analysts predict that ImmunityBio, Inc. will post -0.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on IBRX shares. D. Boral Capital reissued a "buy" rating and set a $23.00 target price on shares of ImmunityBio in a report on Tuesday, May 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ImmunityBio in a report on Friday, July 10th. BTIG Research reaffirmed a "buy" rating and issued a $12.00 price target on shares of ImmunityBio in a report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of ImmunityBio in a research report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, ImmunityBio currently has an average rating of "Moderate Buy" and an average price target of $14.20.

ImmunityBio Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source